Aptevo Therapeutics (NASDAQ:APVO) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a report released on Thursday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Roth Mkm reduced their price target on shares of Aptevo Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, September 23rd.

Aptevo Therapeutics Stock Down 3.7 %

Shares of Aptevo Therapeutics stock opened at $0.26 on Thursday. Aptevo Therapeutics has a 12-month low of $0.14 and a 12-month high of $11.45. The stock’s fifty day moving average is $0.24 and its 200-day moving average is $0.46.

Aptevo Therapeutics (NASDAQ:APVO) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.93) by $0.26. As a group, sell-side analysts predict that Aptevo Therapeutics will post -2.97 EPS for the current fiscal year.

Institutional Investors Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC bought a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned 18.36% of Aptevo Therapeutics at the end of the most recent reporting period. Institutional investors own 8.06% of the company’s stock.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.